###### Key messages

What is the key question?
=========================

-   Are respiratory symptoms more common in people living with HIV, and what effect has antiretroviral therapy had on this?

What is the bottom line?
========================

-   Our study suggests that respiratory impairment remains more common in HIV-positive adults despite the use of antiretroviral therapy.

Why read on?
============

-   This is the first systematic evaluation of existing evidence regarding respiratory symptoms in people living with HIV, summarising the current evidence base and highlighting where deficiencies in this exist.

Introduction {#s1}
============

Antiretroviral therapy (ART) has altered the natural history of HIV-associated respiratory illness such that acute, life-threatening opportunistic respiratory infections (eg, Pneumocystis pneumonia) are much less common. This has reduced the incidence of AIDS-related respiratory pathology, for instance, there is clear evidence of a reduction in the incidence of TB after ART in all CD4 count strata.[@R1] This means that HIV infection can be a manageable chronic illness, with people on ART having a life expectancy approaching that of the general population.[@R2] However, HIV-positive people appear to continue to have an increased frequency of respiratory illness compared with the general population.[@R3] This is important given that respiratory conditions are likely to become more common as populations age.

There is evidence from multiple sources of lung function impairment in people with long-standing HIV infection.[@R4] [@R5] Although most current evidence comes from cohorts in the USA or Europe and less is known about populations in other settings, higher rates of respiratory pathology despite antiretroviral treatment have been a consistent finding of studies in HIV-positive populations.[@R6] There are likely to be several reasons for this, including higher rates of smoking and recreational drug use, lung injury occurring prior to antiretroviral treatment and possible consequences of the ongoing immune activation and disordered immune responses associated with HIV.[@R9]

Although objective impairment of lung function has received considerable recent attention, less attention has been paid to the symptoms that such individuals may experience. This is important, as lung function impairment can correlate poorly with symptoms and functional status.[@R10] We sought, therefore, to provide a comprehensive analysis of existing data regarding respiratory symptoms in people living with HIV with the aim of understanding how this might have changed with ART, and where deficiencies in the current evidence base exist.

We provide a systematic review of the evidence regarding respiratory symptoms from population-based studies directly comparing HIV-positive and HIV-negative individuals with or without ART in both resource-limited and resource-rich settings, and a meta-analysis of the effect of HIV infection on the prevalence of these symptoms.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

Our aim was to evaluate evidence regarding the relative frequency of respiratory symptoms in HIV-positive and HIV-negative populations. We chose search terms that would capture any respiratory symptom (excluding those arising from pathology of the ear, or of obstructive sleep apnoea). We did not seek to set rigid definitions, for instance, regarding the duration of symptoms required to distinguish chronic from acute cough, and instead used those provided by the investigators of the primary studies. This review was registered with the PROSPERO database and details of the protocol are available (PROSPERO 2015:CRD42015013762).

We completed a systematic literature search of publications in the MEDLINE, EMBASE, Cochrane and CINAHL databases between 1946 and August 2015, as well as search of abstracts from the Conference of Retroviruses and Opportunistic Infections and International AIDS Society and American Thoracic Society conferences since 1982 where available. Searches were limited to humans and there was no language limitation.

Search terms included 'HIV' OR 'Human Immunodeficiency virus' OR 'AIDS' AND 'Signs and symptoms, respiratory' (MeSH heading) OR 'cough' OR 'breathless' OR 'dyspnea' OR 'haemoptysis' OR 'short of breath' (see online [supplementary appendix 1](#SM1){ref-type="supplementary-material"}).
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Study selection {#s2b}
---------------

Studies were included if they were published in peer-reviewed journals and included both HIV-positive and HIV-negative participants, measured respiratory symptoms in each group and provided quantitative data. All age groups were included in the review and there were no language restrictions.

Exclusion criteria were as follows: studies reporting symptoms of obstructive sleep apnoea (such as hypersomnolence); studies reporting symptoms arising from the ear (such as ear pain, discharge or hearing change); studies that did not include HIV-negative individuals; and studies reporting data with the intention of describing a specific condition (eg, TB, bacterial or *Pneumocystis jirovecii* pneumonia) rather than the occurrence of symptoms within the general or HIV-positive population. This included studies evaluating hospital in-patients alone, as these would not be representative of the population as a whole. We did not exclude population-based studies if, by chance, they contained people with prevalent respiratory conditions as part of the general (HIV-positive or HIV-negative) population under test.

Data extraction {#s2c}
---------------

All abstracts were independently reviewed by two members of the review team. Shortlisted full-text articles were then jointly reviewed by two reviewers based on the inclusion/exclusion criteria. Where necessary, discrepancies were resolved by discussion with a senior member of the team.

Data were extracted on the following study characteristics: study design, date of study, age and gender of participants, prevalence of tobacco smoking, risk of acquisition of HIV, geographical location(s) of study, number of HIV-positive and HIV-negative participants, frequency of respiratory symptoms, description of respiratory symptoms/tool used to evaluate, availability of antiretroviral treatment, treatment provided for the respiratory illness, level of immunocompromise in the HIV-positive group (eg, median blood CD4 count).

The risk of bias in observational studies was assessed using a modified Newcastle Ottawa Scale (see online [supplementary appendix 2](#SM2){ref-type="supplementary-material"});[@R11] the version used by Herzog *et al* for the evaluation of cross-sectional studies was modified with criteria selected appropriate to this field.[@R12] This scale awarded up to eight points to each study: three points for the adequate selection of participants, three points for comparability of the HIV-positive and HIV-negative participants included in the study and two points for the assessment of symptoms and reporting of statistical tests. In this scale, stars are awarded for higher scores in each criterion, giving a total score out of a possible 8 stars. We defined studies of high quality as those that scored 6--8 stars, moderate quality 5 or 6 stars and low quality those with 0--3 stars.
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Statistical analysis {#s2d}
--------------------

The relative prevalence of respiratory symptoms in HIV-positive and HIV-negative groups was compared using ORs: although different definitions of symptoms were used by the investigators of the primary studies (meaning that the absolute prevalence of particular symptoms varied considerably), the relative frequency of symptoms in HIV-positive and HIV-negative participants could be compared by means of ORs, thus allowing estimation of the effect of HIV infection on the likelihood of having these symptoms.

Studies of adults were stratified by location of study into resource-limited and resource-rich settings (which also equated with high and low TB prevalence and high and low HIV prevalence settings) and availability of ART (as reported by the authors). This stratification was undertaken because the aetiology and determinants of respiratory illness were likely to differ between these settings. Studies evaluating children were not included in the quantitative synthesis as these represent a unique population and these studies were highly heterogeneous in methodology and outcome. Meta-analysis was conducted using RevMan V.5.3 (The Cochrane Collaboration, 2014).

Pooled ORs for the presence of specific respiratory symptoms were calculated within each stratum wherever more than one study provided data. The DerSimonian and Laird random effects model was used to account for between-study heterogeneity. Statistical heterogeneity was assessed using the Cochran χ^2^ test and the I^2^ statistic was used to summarise the degree of variation; causes of heterogeneity were further explored by meta-regression. A priori factors chosen for meta-regression were the proportion of HIV-positive individuals with undetectable viral load and the log OR of smoking in HIV-positive versus HIV-negative groups. The possibility that small studies have more extreme results (due to reporting bias) was assessed by the visual inspection of funnel plots.

Results {#s3}
=======

A total of 5788 publications were identified by our database search after removal of duplicate publications. Of these, 5596 were excluded after review of the article title and abstract. One hundred and ninety-two potentially relevant articles were reviewed in full text, of which 154 were excluded; reasons for exclusion are given in [figure 1](#THORAXJNL2016208657F1){ref-type="fig"}. Twenty-four publications were included in the final list for review ([table 1](#THORAXJNL2016208657TB1){ref-type="table"}). Using a modified Newcastle Ottawa Scale, 6 studies were rated as low quality, 14 as moderate quality and 4 as high quality (see online [supplementary appendix](#SM3){ref-type="supplementary-material"} 3).

###### 

Studies included in this review

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author and reference              Year of publication   Design of study              Risk for HIV            Study location             Total number of participants   \% HIV+   Respiratory data collected                                                                                             Quality rating\*
  --------------------------------------- --------------------- ---------------------------- ----------------------- -------------------------- ------------------------------ --------- ---------------------------------------------------------------------------------------------------------------------- ------------------
  Lepage[@R13]                            1991                  Cross-sectional              General population      Rwanda                     431                            50        Persistent cough \>1 month                                                                                             Moderate

  el Sadr[@R14]\                          1992                  Prospective cohort†          IDU‡                    USA                        223                            56        Standardised symptom checklist (SCS22)                                                                                 Moderate
  Multicentre AIDS Cohort Study                                                                                                                                                                                                                                                                                 

  Hoover[@R15]\                           1993                  Prospective cohort†          MSM                     USA                        2854                           29        New or unusual cough                                                                                                   Moderate
  Multicentre AIDS Cohort Study Visit 3                                                                                                                                                                                                                                                                         

  Hoover---visit 7                        1993                  Prospective cohort†          MSM                     USA                        2627                           29        New or unusual cough                                                                                                   

  Norrgren[@R16]                          1998                  Cross-sectional              General population      Guinea-Bissau              2215                           9         Cough \>1 month                                                                                                        Moderate

  Spira[@R17]                             1999                  Prospective (birth) cohort   Vertical transmission   Rwanda                     401                             13       Persistent cough                                                                                                       Moderate

  Olayinka[@R18]                          1999                  Prospective (birth) cohort   Vertical transmission   Zimbabwe                   272                            16        Cough since last review                                                                                                Low

  Nilses[@R19]                            2000                  Cross-sectional              General population      Zimbabwe                   1213                           22        Dyspnoea, cough                                                                                                        Moderate

  Taha[@R20]                              2000                  Prospective (birth) cohort   Vertical transmission   Malawi                     808                            24        History of wheezy illness collected at clinic appointments                                                             Moderate

  Diaz[@R21]                              2003                  Cross-sectional              MSM                     USA                        379                             86       ATS-DLD-78 questionnaire‡                                                                                              Moderate

  Galli[@R22]                             2003                  Prospective (birth) cohort   Vertical transmission   Italy                      2060                           4         Retraction of intercostal muscles, wheezes, cough, active nasal flaring or rales at follow-up visits                   Low

  Lewis[@R23]                             2009                  Cross-sectional              General population      South Africa               1955                            29       New or worsening cough (\>2 weeks or \>3 weeks)\                                                                       Moderate
                                                                                                                                                                                         Haemoptysis                                                                                                            

  Read[@R24]                              2009                  Prospective (birth) cohort   Vertical transmission   Malawi, Tanzania, Zambia    1317                          6         Chronic cough (\>14 days)                                                                                              Moderate

  Kheaw-On[@R25]                          2009                  Cross-sectional              General population      Thailand                   210                            50        History of chronic cough                                                                                               Low

  Corbett[@R26]                           2010                  Cross-sectional              General population      Zimbabwe                   8979                           21        Cough \<2 weeks. Cough \>3 weeks, haemoptysis                                                                          Low

  Drummond[@R27]\                         2010                  Prospective cohort†          IDU                     USA                        974                            30        Modified ATS-DLD-78\                                                                                                   High
  ALIVE cohort                                                                                                                                                                           MRC dyspnoea scale                                                                                                     

  Onyedum[@R28]                           2010                  Cross-sectional              General population      Nigeria                    200                            50        Cough, cough with sputum, breathlessness, wheezing                                                                     Low

  Gounder[@R29]                           2011                  Cross-sectional              General population      South Africa               3937                           37        Cough \>2 weeks. Sputum production                                                                                     Moderate

  Crothers[@R8]\                          2013                  Prospective cohort†          Mixed                   USA                        589                            51        Usual cough/phlegm, wheezing (ATS-DLD-78)\                                                                             High
  Lung HIV Study                                                                                                                                                                         MRC dyspnoea scale                                                                                                     

  Fitzpatrick[@R7]\                       2013                  Prospective cohort†          Mixed                   USA                        99                             64        ATS-DLD questionnaire                                                                                                  High
  WHIS                                                                                                                                                                                                                                                                                                          

  Madeddu[@R30]                           2013                  Cross-sectional              MSM                     Italy                      176                            63        Symptom questionnaire\                                                                                                 Moderate
                                                                                                                                                                                         MRC dyspnoea scale                                                                                                     

  Antwal[@R31]                            2014                  Cross-sectional              Not detailed            India                      1546                           35        Breathlessness, cough with sputum                                                                                      Moderate

  Campo[@R32]\                            2014                  Prospective cohort†          Mixed                   USA                        340                            53        Chronic cough (for most days for 3 months or more per year for \>1 year), chronic phlegm, wheeze, MRC dyspnoea scale   Moderate
  EXHALE substudy, VACS cohort                                                                                                                                                                                                                                                                                  

  Gingo[@R33] (MACS)                      2014                  Prospective cohort†          MSM                     USA                        1896                           48        ATS-DLD-78 questionnaire                                                                                               High

  Gingo (WIHS)                            2014                  Prospective cohort†          Mixed                   USA                        1976                           71        ATS-DLD-78 questionnaire                                                                                               

  Telisinghe[@R34]\                       2014                  Cross-sectional              General population      South Africa               846                            25        Chronic cough (\>14 days)                                                                                              Low
  Prison cohort                                                                                                                                                                                                                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Modified Newcastle Ottawa Scale.

†Data arising from prospective cohort studies; however, data used in quantitative analyses for this review from single time point.

‡American Thoracic Society Division of Lung Disease questionnaire.

IDU, injection drug user; MACS, Multi-Centre AIDS Cohort Study; MSM, men who have sex with men; VACS, Veterans Aging Cohort Study; WIHS, Women\'s Interagency HIV Study.

![Flow chart of study selection.](thoraxjnl-2016-208657f01){#THORAXJNL2016208657F1}
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Characteristics of included studies and data presented {#s3a}
------------------------------------------------------

All studies included were observational studies, although two papers investigated cohorts recruited as part of randomised trials.[@R20] [@R24] With the exception of five studies following birth cohorts over time, all studies were either cross-sectional in nature or reported data arising from prospective cohorts at a single time point.

The earliest study recruited patients from 1985,[@R15] with the most recent provided data collected in 2012.[@R32] Eight articles reported research conducted in the USA (detailing 9 separate studies), with 12 studies conducted in Africa, 2 in Asia and 2 in Europe (both from Italy). Nineteen studies included adult patients and five evaluated infants only.

The presence of cough and breathlessness were the most common symptoms evaluated: data on cough were presented by 17 of 19 studies in adults. Definitions of cough varied, with the most common being the presence of cough for \>2 weeks ([tables 2](#THORAXJNL2016208657TB2){ref-type="table"}[](#THORAXJNL2016208657TB3){ref-type="table"}[](#THORAXJNL2016208657TB4){ref-type="table"}[](#THORAXJNL2016208657TB5){ref-type="table"}--[6](#THORAXJNL2016208657TB6){ref-type="table"}). Frequency of breathlessness was reported by 11 studies. Usually this was defined only as the presence of 'dyspnoea', 'breathlessness' or 'shortness of breath', though four studies (all evaluating adults with access to ART) used the Medical Research Council (MRC) dyspnoea score as a standardised measure.[@R35]

###### 

Respiratory symptoms in resource-limited settings without access to ART

  First author     Year of publication   Study location   Total N   \% HIV+   HIV+ on ART (%)   Mean/median blood CD4\*   \% HIV+ Smokers   \% HIV− smokers   Definition of cough used               \% HIV+ with cough   \% HIV− with cough   Definition of breathlessness   \% HIV+ with breathlessness   \% HIV− with breathlessness
  ---------------- --------------------- ---------------- --------- --------- ----------------- ------------------------- ----------------- ----------------- -------------------------------------- -------------------- -------------------- ------------------------------ ----------------------------- -----------------------------
  Lepage[@R13]     1991                  Rwanda           431       50        0                 24% CD4:CD8 \<0.5         NR                NR                Persistent cough \>1 month             14                   7                                                                                 
  Norrgren[@R16]   1998                  Guinea-Bissau    2215      9         0                 715 (men) 430 (women)     NR                NR                Cough \>1 month                        3                    1                                                                                 
  Nilses[@R19]     2000                  Zimbabwe         1213      21        0                 NS                        NR                NR                Cough                                  4                    2                    Dyspnoea                       1                             1
  Kheaw-On[@R25]   2009                  Thailand         210       50        NR                261                       36                15                History of chronic cough               57                   31                                                                                
  Lewis[@R23]      2009                  South Africa     1955      29        NR                NR                        NR                NR                New or worsening cough, any duration   4                    2                                                                                 
   \>2 weeks       2                     1                                                                                                                                                                                                                                                                  
   \>3 weeks       2                     1                                                                                                                                                                                                                                                                  
  Corbett[@R26]    2010                  Zimbabwe         8979      21        NR                NR                        NR                NR                Cough for 2 weeks or more              8                    2                                                                                 
  Onyedum[@R28]    2010                  Nigeria          200       50        0                 71% CD4 \<200             0                 0                 Cough                                  48                   8                    Breathlessness                 32                            0
  Gounder[@R29]    2011                  South Africa     3937      37        NR                333                       NR                NR                Cough for 2 weeks or longer            7                    4                                                                                 
  Antwal[@R31]     2014                  India            1546      35        0                 241                       NR                NR                Cough with sputum                      10                   2                    Breathlessness                 4                             1

\*Cells per microlitre unless otherwise stated.

ART, antiretroviral therapy; NR, not reported.

###### 

Studies in resource-rich settings without access to ART

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                                   Year   Study location   Total number of participants                                                                                 \% HIV+   Risk for HIV   HIV+ on ART (%)   Mean/median blood CD4\*   \% HIV+ Smokers   \% HIV− smokers   Definition of cough used                 \% HIV+ with cough   \% HIV− with cough   Definition of breathlessness                                                                      \% HIV+ with breathlessness   \% HIV− with breathlessness
  ---------------------------------------------- ------ ---------------- ------------------------------------------------------------------------------------------------------------ --------- -------------- ----------------- ------------------------- ----------------- ----------------- ---------------------------------------- -------------------- -------------------- ------------------------------------------------------------------------------------------------- ----------------------------- -----------------------------
  el Sadr[@R14]                                  1992   USA              223                                                                                                          56        IDU            0                 200--500                  NR                NR                Persistent cough                         17                   7                                                                                                                                                    

  Hoover visit 3[@R15]                           1993   USA              2854                                                                                                         33        MSM            0                 619                       NR                NR                New or unusual cough lasting \>2 weeks   5                    2                    Persistent shortness of breath                                                                    1                             2

  Hoover---visit 7                               1993   USA              2627                                                                                                         29        MSM            0                 552                       NR                NR                5                                        2                    3                    2                                                                                                                               

  Diaz[@R21]                                     2003   USA              379                                                                                                          86        MSM            0                 370                       54                50%               Do you usually have a cough?             40                   25                   Are you troubled by shortness of breath when hurrying on the level or walking up a slight hill?   42                            8

  Do you usually cough like this on most days\   24     12               Do you have to walk slower than most people of your own age on the level ground because of breathlessness?   20        0                                                                                                                                                                                                                                                                                                                 
  For ≥3 consecutive months of the year?                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Cells per microlitre.

ART, antiretroviral therapy; IDU, injection drug user; MSM, men who have sex with men.

###### 

Studies evaluating children (cohorts followed up from birth)

  First author     Year of publication   Study location             Total number of participants   \% HIV+   \% HIV+ on ART   Duration of follow-up (from birth)                                      Respiratory data collected                                                                             Notes/comments
  ---------------- --------------------- -------------------------- ------------------------------ --------- ---------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------
  Spira[@R17]      1999                  Rwanda                     401                            13        0                Median 27 months (HIV-positive group), 51 months (HIV-negative group)   Chronic cough (\>14 days)                                                                              Measured cumulative incidence of developing a cough lasting \>14 days
  Olayinka[@R18]   1999                  Zimbabwe                   272                            16        0                24 months                                                               Persistent cough                                                                                       
  Taha[@R20]       2000                  Malawi                     689                            19        0                Median 18 months                                                        Cough since last review                                                                                2 HIV-negative groups---exposed uninfected infants and unexposed. Rate of cough the same in each.
  Galli[@R22]      2003                  Italy                      280                            75        25               24 months                                                               History of wheezy illness collected at clinic appointments                                             Presents proportion of infants with wheezy illness in first 2 years of life
  Read[@R24]       2009                  Malawi, Tanzania, Zambia    1317                          84        0                12 months                                                               Retraction of intercostal muscles, wheezes, cough, active nasal flaring or rales at follow-up visits   HPTN 024 study cohort, studied 2001--2004

ART, antiretroviral therapy; HPTN, The HIV Prevention Trials Network.

###### 

Studies evaluating populations in resource-rich settings with access to ART

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                           Year   Study location   Total number of participants   \% HIV+   HIV+ on ART (%)   \% undetectable HIV plasma load   Mean/median blood CD4   \% HIV+ smokers   \% HIV− smokers   Definition of cough   \% HIV+ with cough   \% HIV− with cough   Definition of breathlessness   \% HIV+ with breathlessness   \% HIV− with breathlessness
  -------------------------------- ------ ---------------- ------------------------------ --------- ----------------- --------------------------------- ----------------------- ----------------- ----------------- --------------------- -------------------- -------------------- ------------------------------ ----------------------------- -----------------------------
  Drummond[@R27]\                  2010   USA              974                            30        54                16.5                              320                     83                86                Cough present          3                   29                   MRC dyspnoea score ≥2          35                            28
  ALIVE cohort                                                                                                                                                                                                                                                                                                                                   

  Morning cough ≥4 days per week   19     19                                                                                                                                                                                                                                                                                                     

  Morning cough ≥3 months          15     15                                                                                                                                                                                                                                                                                                     

  Crothers[@R8]\                   2013   USA              589                            51        89                84                                493                     47                35                Unusual cough         28                   20                   MRC dyspnoea score ≥2          15                            11
  Lung HIV Study                                                                                                                                                                                                                                                                                                                                 

  Fitzpatrick[@R7]\                2013   USA              99                             64        81                NS                                426                     46                50                                                                                Dyspnoea                       35                            31
  WIHS                                                                                                                                                                                                                                                                                                                                           

  Madeddu[@R30]                    2013   Italy            176                            63        78                71                                541                     57                58                Cough                 32                   14                   MRC dyspnoea score ≥2          31                            15

  Campo[@R32]\                     2014   USA              340                            53        89                NS                                431                     64                58                Chronic cough         25                   16                   MRC dyspnoea score ≥2          25                            16
  EXHALE substudy, VACS cohort                                                                                                                                                                                                                                                                                                                   

  Gingo[@R33]\                     2014   USA              1896                           48        77                70                                572                     31                23                Cough                 42                   38                   Dyspnoea                       14                            9
  MACS                                                                                                                                                                                                                                                                                                                                           

  Gingo\                           2014   USA              1976                           71        76                56                                502                     39                52                Cough                 54                   58                   Dyspnoea                       36                            37
  WIHS                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ART, antiretroviral therapy; MACS, Multi-Centre AIDS Cohort Study; VACS, Veterans Aging Cohort Study; WIHS, Women\'s Interagency HIV Study.

###### 

Studies evaluating populations in resource-limited settings with access to ART

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author              Year   Study location   Total number of participants   \% HIV+   HIV+ on ART (%)   \% Undetectable HIV plasma load   Mean/median blood CD4   \% HIV+ smokers   \% HIV− smokers   Definition of cough   \% HIV+ with cough   \% HIV− with cough
  ------------------- ------ ---------------- ------------------------------ --------- ----------------- --------------------------------- ----------------------- ----------------- ----------------- --------------------- -------------------- --------------------
  Telisinghe[@R34]\   2014   South Africa     846                            25        41                NS                                NS                      59                59                Cough \>2 weeks       13                   8
  Prison cohort                                                                                                                                                                                                                                   

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ART, antiretroviral therapy.

Studies that examined respiratory symptoms in HIV-positive adults without access to ART {#s3b}
---------------------------------------------------------------------------------------

Twelve studies provided data regarding respiratory symptoms in HIV-positive adults without access to ART ([tables 2](#THORAXJNL2016208657TB2){ref-type="table"} and [3](#THORAXJNL2016208657TB3){ref-type="table"}). All of these demonstrated a greater proportion of HIV-positive participants with respiratory symptoms. Five studies reported prevalence of breathlessness (two from the USA, others from Nigeria, Zimbabwe and India).

Three studies provided data on respiratory symptoms in HIV-positive populations in the first decade of the HIV epidemic in the USA. The Multicenter AIDS Cohort Study collected data from a cohort of MSM at four sites from 1985 onwards; el Sadr *et al* studied a cohort of injection drug users in New York and Diaz *et al* evaluated a cohort of predominantly white men in Ohio. Data on respiratory symptoms in these populations are presented in [table 3](#THORAXJNL2016208657TB3){ref-type="table"}.

Nine studies reported the prevalence of respiratory symptoms in HIV-positive and HIV-negative individuals without access to ART in resource-limited settings, and seven of these were in sub-Saharan African populations. The earliest of these used data from Rwanda collected in 1988, and the most recent was from Antwal *et al* in 2014. Only two studies evaluated populations outside of the USA and Africa (Kheaw-on *et al* in Cambodia and Antwal *et al* in India).

Studies that examined symptoms in HIV-positive children {#s3c}
-------------------------------------------------------

Five studies reported the prevalence of respiratory symptoms in HIV-positive and HIV-negative children ([table 4](#THORAXJNL2016208657TB4){ref-type="table"}). All of these evaluated cohorts of vertically infected infants followed up from birth, and no studies assessed older children. The earliest was conducted in Rwanda from 1988 with subsequent work in Malawi and Zimbabwe. None of these study populations had access to ART.

One study evaluated symptoms in HIV-positive infants born in Chieti, Italy; this suggested a lower frequency of 'wheezy respiratory illness' in HIV-positive infants despite more maternal smoking, premature delivery, low birth rate and formula feeding. However, the design of the study (based on routine clinic records) did not allow appraisal of the possibility of differences in health-seeking behaviour or reporting of acute respiratory illness, which could bias the comparison of respiratory symptoms between the different groups.

Studies that examined respiratory symptoms in HIV-positive adults with access to ART {#s3d}
------------------------------------------------------------------------------------

Six studies (using data from seven cohorts) reported on adults with access to ART. All were from resource-rich settings other than one from South Africa. Data on respiratory symptoms are presented in [tables 5](#THORAXJNL2016208657TB5){ref-type="table"} and [6](#THORAXJNL2016208657TB6){ref-type="table"}.

All contained a high proportion of current smokers in both the HIV-positive and HIV-negative groups and, where reported, often had high rates of former or ongoing recreational drug use.

The first systematic comparison of respiratory symptoms in a HIV-positive population with access to ART with HIV-negative comparators is provided by the AIDS Linked to the IntraVenous Experience (ALIVE) cohort of former and current injection drug users in Baltimore, Maryland, USA.[@R27] This found no difference in frequency of current cough, although a history of 'wheezing' was reported by 50% of HIV-positive and 37% of HIV-negative participants.

Several cohort studies have addressed respiratory symptoms in HIV-positive individuals with access to ART in the USA: the Women\'s Interagency HIV Study (WIHS); Multicentre AIDS Cohort Study and the EXHALE substudy of the Veterans Aging Cohort Study.[@R32] [@R36] Tobacco use was high in these cohorts, and smoking was more frequent in the HIV-positive than HIV-negative groups (reported in 39%--64% and 23%--58%, respectively). The prevalence of respiratory symptoms was high in these populations, for instance Fitzpatrick *et al*[@R7] described breathlessness in 35% of HIV-positive and 31% HIV-negative participants in the WIHS study and Campo *et al* [@R32] reported cough in 25% of HIV-positive and 16% in HIV-negative participants in the EXHALE VACS substudy.

There is little information comparing respiratory symptoms in HIV-negative and HIV-positive individuals with access to ART outside of North America. The only study providing data from Europe documented the presence of any respiratory symptom in 47% HIV-positive participants and 23% of HIV-negative participants, with 32% vs 14% reporting cough (p=0.006) and 31% vs 15% breathlessness (p=0.02).[@R30] Telisinghe *et al*[@R34] evaluated a prison population in South Africa (with a 25% HIV prevalence) in which cough lasting 2 weeks or more was present in 13% of HIV-positive and 8% of HIV-negative individuals. 36% of the HIV-positive participants reported the use of ART.

The prevalence of tobacco smoking was only consistently reported in studies undertaken in resource-rich settings with access to ART. In all of these studies, a large proportion of both HIV-positive and HIV-negative participants were current smokers (see [table 5](#THORAXJNL2016208657TB5){ref-type="table"}), and this was similar across these groups.

Quantitative data synthesis {#s3e}
---------------------------

Data were available on 12 075 HIV-positive individuals compared with 24 450 individuals without HIV infection. The symptoms for which sufficient data were available to allow quantitative synthesis were cough and breathlessness. [Figures 2](#THORAXJNL2016208657F2){ref-type="fig"} and [3](#THORAXJNL2016208657F3){ref-type="fig"} demonstrate the ORs for the presence of cough and breathlessness in those with and without access to ART and in resource-rich and resource-limited settings.

![Forest plot of ORs for presence of cough, stratified by availability of ART and location. ART, antiretroviral therapy; MACS, Multicentre AIDS Cohort Study; WIHS, Women\'s Interagency HIV Study.](thoraxjnl-2016-208657f02){#THORAXJNL2016208657F2}

![OR for the presence of breathlessness, random effects meta-analysis stratified by location and availability of antiretroviral therapy.](thoraxjnl-2016-208657f03){#THORAXJNL2016208657F3}

Meta-anaysis suggests that the availability of ART is associated with a reduction in the difference in prevalence of respiratory symptoms between HIV-positive and HIV-negative individuals, yet these remain more common in people living with HIV. There is little evidence regarding respiratory symptoms in HIV-positive populations in resource-limited settings. The pooled OR for the presence of cough in such populations without access to ART was 3.05 (95% CI 2.24 to 4.16, I^2^=68%); in resource-rich populations without access to ART, it was 2.18 (1.55 to 3.04 I^2^=0%), and in those from resource-rich settings with access to ART, the OR for the presence of cough was 1.26 (0.97 to 1.63)---although there was a substantial degree of heterogeneity in this analysis (I^2^=74%). Only one study reported frequency of cough in a high-prevalence setting with access to ART.[@R34]

Breathlessness was also assessed, although fewer studies reported this. In resource-limited settings without access to ART, the OR for the presence of breathlessness was 7.5 (0.92 to 61.31, I^2^=83%). Only two studies were available from resource-rich settings without access to ART, and meta-analysis of these data provides an OR of 2.60 (0.25 to 26.93, I^2^=93%). In resource-rich settings with access to ART, there was good evidence for a higher rate of breathlessness in HIV-positive individuals with an OR of 1.39 (1.11 to 1.73, I^2^=52%).

Funnel plots were inspected to evaluate the possibility of reporting or publication bias where sufficient studies were available within each stratum of ART availability and location to make this useful. For the most part these did not suggest the presence of significant reporting bias (eg, see online [supplementary figure S1](#SM4){ref-type="supplementary-material"}) although this was possible for the apparent association between breathlessness in HIV-positive populations with access to ART (see online [supplementary figure S2](#SM4){ref-type="supplementary-material"}). As there were fewer than 10 studies within each stratum, quantitative tests of reporting bias were not used, in accordance with the Cochrane Handbook guidance.[@R37]
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Sensitivity analyses {#s3f}
--------------------

Two studies (Onyedum 2010 and Antwal 2014) included in the analysis of respiratory symptoms in populations without access to ART were judged to be at high risk of bias due to the inclusion of significant numbers of participants presenting for care with acute respiratory illnesses due to their methodology (which involved recruitment within acute care services).[@R32] [@R33] Exclusion of these studies reduced somewhat the effect size for the prevalence of cough to an OR of 2.84 (2.45 to 3.30) as well as the heterogeneity in this analysis (I^2^=55%).

Four studies (all in populations with access to ART) used the MRC dyspnoea scale to measure breathlessness (see [table 5](#THORAXJNL2016208657TB5){ref-type="table"}). A meta-analysis including only studies using the MRC dyspnoea scale (with breathlessness defined as a score of ≥2) did not significantly change the effect size (compared with the analysis of all studies reporting the prevalence of breathlessness in populations with access to ART) but reduced heterogeneity significantly (OR for having MRC dyspnoea ≥2=1.50, 95% CI 1.21 to 1.85, I^2^=0%, online [supplementary figure S3](#SM4){ref-type="supplementary-material"}).

The true effect of HIV status on respiratory symptoms may be exaggerated by the higher proportion of HIV-positive subjects who were current smokers in several of the included studies, as few studies provided data adjusted for smoking status. Meta-regression confirmed an association between higher rates of respiratory symptoms in studies with a greater imbalance of smokers versus non-smokers in the HIV-positive compared with HIV-negative group (data not shown). However, this had little impact on the estimated effect of HIV infection on the frequency of cough or breathlessness.

Discussion {#s4}
==========

This systematic review and meta-analysis demonstrates that despite the availability of ART, HIV-positive populations continue to experience more respiratory symptoms than comparable HIV-negative groups, at least in resource-rich settings for which there are sufficient data to draw conclusions. It also highlights several research needs: in particular the lack of rigorous data concerning respiratory symptoms in HIV-positive populations in low-income and middle-income settings where the majority of the world\'s HIV-positive individuals live.

The successful provision of ART means that HIV-positive populations can expect considerable improvements in life expectancy;[@R38] however, ageing HIV-positive populations have more comorbidities and respiratory illness is likely to become increasingly important over time.[@R39] [@R40] An improved understanding of the health needs of ageing HIV-positive populations is required, as even in resource-rich settings, the impact of respiratory illness on individuals (measured by instruments designed to evaluate health-related quality of life) or at a societal health-economic level is evaluated infrequently in HIV-positive populations.

In resource-rich settings, HIV-positive populations often have greater cigarette and recreational drug use than the general population.[@R41] [@R42] Interventions to reduce this are therefore important, given that there is accumulating evidence of increased rates of both cardiovascular and respiratory illness. In some high HIV prevalence settings, tobacco smoking is rising fast,[@R43] and attention should be given to the possibility that HIV-positive individuals may be particularly susceptible to the harmful effects of tobacco smoking.[@R44]

Strengths of this analysis include a comprehensive search strategy and robust methods for study selection. Limitations include the lack of standardised assessments of respiratory symptoms in the primary studies, and incomplete reporting of important confounding factors (eg, smoking and recreational drug use), which may influence the effect sizes found. The incomplete reporting of exposures such as tobacco smoking and drug use in the original papers means that the extent to which the association identified between HIV status and respiratory symptoms is a direct result of the HIV virus is uncertain as we were not able to adjust for differing exposures to these possible confounding factors between HIV-positive and HIV-negative individuals. Another important limitation is that the data included in the quantitative meta-analyses were cross-sectional in nature and we cannot therefore infer causation from such studies. Bias or confounding in the primary studies may be one cause of the association between HIV status and respiratory symptoms found, and the strength of conclusions that can be drawn is therefore limited by the paucity of evidence in many areas.

One difficulty when evaluating respiratory symptoms is the challenge of standardising assessments: The wide range in the reported frequency of respiratory symptoms arises in part from the diversity of methods used to evaluate them: the definitions used for symptoms such as cough or breathlessness were often not stated, and a minority of studies used validated tools such as the St George\'s Respiratory Questionnaire,[@R45] American Thoracic Society Division of Lung Disease questionnaire[@R46] or the MRC dyspnoea scale (see [tables 2](#THORAXJNL2016208657TB2){ref-type="table"}[](#THORAXJNL2016208657TB3){ref-type="table"}[](#THORAXJNL2016208657TB4){ref-type="table"}[](#THORAXJNL2016208657TB5){ref-type="table"}--[6](#THORAXJNL2016208657TB6){ref-type="table"} for details of data collected in each study).[@R35] Furthermore, results were presented as the proportion/number with respiratory symptoms, with no study reporting estimates adjusted for potential confounders.

It is important to note that although populations may have access to ART, most studies include a significant proportion of participants who were either not using ART, or who do not have an undetectable viral load. We cannot therefore estimate the effect of HIV infection at an individual level in those with a favourable virological and immunological response to ART. Furthermore, most of the data regarding populations with access to ART derive from the USA and there is limited information from other settings. Exposures of importance that could lead to respiratory disease may differ in other locations, and the findings of the studies included in this review may not be generalisable---for instance, to HIV-positive African populations using ART.

Our analysis suggests that despite the availability of ART, HIV-positive individuals are more likely to experience respiratory symptoms than those without HIV. Part of the reason for this higher burden of symptoms is likely to be the greater prevalence of tobacco smoking and recreational drug use in many HIV-positive populations, particularly in resource-rich countries. However, direct HIV-related mechanisms may also play a role: although ART treatment achieves virological suppression for the majority of people treated, derangements of immune function persist despite treatment, which include evidence of ongoing immunological activation, which may promote the development of comorbid disease.[@R47] There is growing evidence that this is clinically important for the development of cardiovascular disease[@R48] and may also be relevant for respiratory pathology---for instance, Attia *et al* demonstrated an association between soluble CD14 (a marker of immune activation) and radiological emphysema in HIV-positive adults.[@R4]

Interventions are required to address this health need. For populations with high levels of tobacco smoking, smoking cessation services should be prioritised. Earlier and more successful ART treatment may yield better lung health in the long term, although no significant differences in respiratory symptoms or lung function change were seen in HIV-positive adults with CD4 counts above 500 cells/µL randomised to early compared with deferred ART treatment in the recent START trial.[@R49]

Furthermore, as highlighted in this review, there is little available evidence regarding the determinants of respiratory illness in HIV-positive individuals in resource-limited settings, where the majority of the world\'s HIV-positive individuals live.
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